ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 318

Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic

Francine Castillo1, Michael Dodge 1, Jung Hee Noh 2, Laura Trupin 1, Jinoos Yazdany 3 and Sarah Goglin 3, 1University of California, San Francisco, San Francisco, CA, 2Zuckerberg San Francisco General Hospital, San Francisco, CA, 3UCSF Division of Rheumatology, San Francisco, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: hydroxychloroquine and systemic lupus erythematosus (SLE), quality improvement

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and with prolonged use. In 2016, the American Academy of Ophthalmology (AAO) modified its HCQ dosing and screening guidelines to recommend a maximum daily dose of 5 mg/kg of actual body weight and retinal examinations at baseline, then annually after 5 years of taking HCQ. We undertook a quality improvement project in a safety net rheumatology clinic that had two aims: 1) to increase the proportion of patients prescribed hydroxychloroquine at recommended doses from 85% at baseline to 95% and 2) to improve the proportion of patients receiving appropriate retinal screening from 52% at baseline to 80% at one year. 

Methods: Using the Institute for Healthcare Improvement’s Model for Improvement, we first mapped the existing clinical workflow for HCQ prescribing and monitoring. We developed and applied two process measures to track our progress: the proportion of patients prescribed hydroxychloroquine receiving a dose less than or equal to 5 mg/kg at their last encounter and the proportion of patients prescribed hydroxychloroquine at their last encounter with a retinal screening test over the last 18 months.  After identifying baseline values for our two process measures, we worked with clinicians and clinic support staff over four Plan-Do-Study-Act (PDSA) cycles to develop our intervention. The final optimized workflow involved the clinic’s nurse using a weekly report to identify patients who were overdue for retinal screening for an ophthalmology referral and to alert physicians whose patients were on a higher than recommended dose of HCQ.  In September 2018, we queried the electronic health record again for data on our clinic’s adherence rates to AAO guidelines between September 2017 to August 2018 to analyze the impact of our intervention.

Results: The percentage of clinic patients prescribed HCQ at doses less than 5.0 mg/kg daily increased from 84% to 86% during the study period, and the percentage receiving retinal screening increased from 64% to 76%. Of note, only 8 out of the 243 SLE patients on HCQ with a rheumatology office visit in 2018 did not have an ophthalmology appointment scheduled. The remainder of those that did not have retinal screening had an ophthalmology appointment scheduled, but either cancelled or did not appear to their appointments.

Conclusion: Using the Model for Improvement, we were able to develop and integrate an intervention to increase adherence to the AAO recommendations for HCQ dosing and retinal screening measures, although we fell short of our pre-specified improvement goals. Although the intervention has been moderately effective at improving patient safety practices for this drug, efforts are ongoing to further understand barriers to further improvement, including root cause analysis of individual-level and systems-level factors.


Figure 1_ACR 2019_Castillo_Dodge

Figure 1: Distribution of hydroxychloroquine doses prescribed to rheumatology clinic patients in the periods prior to and after intervention.


Figure 2_ACR 2019_Castillo_Dodge

Figure 2: Frequency of retinal screenings among rheumatology clinic patients treated with hydroxychloroquine in the periods prior to and after intervention.


Disclosure: F. Castillo, None; M. Dodge, None; J. Noh, None; L. Trupin, None; J. Yazdany, Astra Zeneca, 5, Pfizer, 2; S. Goglin, None.

To cite this abstract in AMA style:

Castillo F, Dodge M, Noh J, Trupin L, Yazdany J, Goglin S. Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improving-safe-prescribing-of-hydroxychloroquine-in-a-safety-net-hospital-rheumatology-clinic/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-safe-prescribing-of-hydroxychloroquine-in-a-safety-net-hospital-rheumatology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology